Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

VanEck’s PPH screens as the more income- and cost-efficient option vs Invesco’s PJP, with a lower 0.36% expense ratio (vs 0.57%) and a higher trailing dividend yield (2.00% vs 0.90%). Over the trailing 12 months PJP delivered stronger total return (49.90% vs 27.10%), while PPH lagged less over 5 years, supported by higher AUM ($879.5M vs $358.7M) and greater liquidity. PPH is more top-heavy (largest holding >20% in Eli Lilly at 20.24%), while PJP is more spread out across 29 names.

Analysis

This is less a pharma call than a packaging and factor-exposure call. PPH is effectively a concentrated proxy for a handful of mega-cap defensives, so the real risk is not sector beta but single-name dependence: if LLY de-rates or stumbles on execution, the fund’s drawdown can look much more like an active basket than an ETF. That concentration also means the fund will likely capture upside faster if the GLP-1 complex keeps expanding, but investors are paying for that through uncompensated idiosyncratic risk rather than through a better fundamental screen.

The more interesting second-order effect is flow-driven. In a risk-off tape, income plus lower fees should attract allocators who want healthcare ballast without taking full market beta, which could support PPH relative to PJP over 1-3 months even if fundamentals are unchanged. Over 6-18 months, the edge depends on whether the market continues rewarding U.S.-centric pharma momentum; if that fades, PJP’s higher recent return becomes a poor guide and the cheaper, higher-yield structure should look more attractive to institutions.

Contrarian take: the consensus is overfocusing on trailing performance and underestimating how much of PPH’s “diversification” is actually just a high-conviction bet on a few names. That cuts both ways: if LLY, NVS, and MRK keep compounding, PPH can beat despite the fee advantage alone; if any one of those faces pricing or pipeline disappointment, the ETF’s downside will be more severe than its lower beta suggests. The cleanest falsifier for a PPH-over-PJP preference is continued U.S. pharma leadership led by ABT/ABBV rather than the mega-cap trio, because that would favor the more balanced PJP construction.

Key Decisions for Investors

• If using pharma as a defensive allocation, prefer PPH over PJP for a 6-12 month hold only if you are explicitly comfortable with LLY concentration; otherwise treat PPH as a quasi-single-name basket, not a broad sector sleeve.
• Pair trade for relative value: long PPH / short PJP on any momentum fade in U.S. pharma over the next 1-3 months; thesis is fee plus yield plus liquidity should matter more once price momentum cools. Stop out if PJP keeps outperforming by ~5% on a rolling 2-month basis.
• For investors already long LLY, avoid doubling up through PPH unless the goal is to lever the same GLP-1 factor; PPH increases exposure to the same earnings and regulatory risk without giving much incremental diversification.
• Watch for a rotation into dividend-oriented defensives: if healthcare leadership broadens beyond LLY and the top-3 names, PPH’s concentration premium likely erodes. Falsifier: ABT/ABBV/MRK-led leadership persists and PJP keeps winning on a 3-month relative basis.